Taken together, further research could aid in evaluating the extent that the AT1 receptor in the periphery modulates inflammation in AD-relevant contexts and the development of novel ARBs that display higher brain penetration could limit clinical hypotensive effects of ARBs. Here, AGTR1 is linked to Alzheimer disease.